Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations
02 janv. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing, and commercializing novel antibiotics to treat...
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
29 nov. 2017 07h00 HE
|
Melinta Therapeutics
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® - - Peak sales potential of the...
Melinta Therapeutics Announces Successful Completion of Merger
06 nov. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
10 oct. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
04 oct. 2017 13h13 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios
26 sept. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections
25 sept. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Demonstrates Potential of Pyrrolocytosine Candidate against Gonorrhea
05 juin 2017 12h45 HE
|
Melinta Therapeutics
New Haven, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that an oral...
Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe
01 juin 2017 14h42 HE
|
Melinta Therapeutics
New Haven, Conn, June 01, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that five...